Klaria Pharma Holding ABOMXSTO: KLAR

Klaria Receives EU Notification of Allowance for Sumatriptan Alginate Film

· Issued by Klaria Pharma Holding AB

Summary by 6ix AI

Klaria, a Swedish listed pharmaceutical company that develops a film that attaches to the inside of the mouth, received a Notice of Allowance from the European Patent Office for the second patent in its Sumatriptan Alginate Film (SAF) patent portfolio. The notice indicates the patent and all its claims are to be granted in their entirety.

Key details

  • Klaria says SAF is already protected by granted patents in major market territories such as the EU and US, and that the second patent broadens these protections.
  • Klaria says broader patent protection gives it more flexibility in manufacturing, lets it identify and prosecute patent infringement, and discourages development of similar competing products without its consent.
  • Klaria previously reported a positive opinion on novelty and inventive step, the basic requirements of a valid patent, for a third patent in the SAF family. It says that patent aims to protect the specific properties of the marketed product and extend patent protection, and thus market exclusivity, to 2045.

What’s still pending

  • The second patent is to be granted; the Notice of Allowance is not itself the grant.
  • The third SAF patent has not been granted, so the aimed-for protection to 2045 is not yet in place.

6ix AI wrote this summary from the release below and checked it against the release.

Klaria has received a Notice of Allowance from the European Patent Office for the second patent in the Sumatriptan Alginate Film (SAF) patent portfolio.  The Notice of Allowance indicates that the second patent and all claims therein are to be granted in their entirety.

SAF is already protected by granted patents in the major market territories, such as the EU and US and the granting of the second patent broadens these protections.  Patent protection of a marketed product is seldom through a single patent.  Broadening protections through additional patents allows Klaria more flexibility in manufacturing, but more importantly it allows Klaria to identify and prosecute patent infringement and discourages development of similar, competing products without Klaria's consent.

Earlier this year, Klaria announced a positive opinion on both novelty and inventive step, the fundamental requirements of a valid patent, on the third patent in the SAF patent family.  The aim of the third patent is to protect the specific properties of the marketed product and to extend the patent protection and thus market exclusivity to 2045.  Klaria looks forward to announcing progress on this patent in the future.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:

Fredrik Hübinette, Chairman of the Board of Directors
[email protected]
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor ([email protected], +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.

https://news.cision.com/klaria-pharma-holding-ab/r/klaria-receives-eu-notification-of-allowance-for-sumatriptan-alginate-film,c4381031

https://mb.cision.com/Main/12655/4381031/4211693.pdf

(c) 2026 Cision. All rights reserved., source Press Releases - English

Klaria Pharma Holding AB on 6ix

Story so far

Earlier from Klaria Pharma

Later from Klaria Pharma

All Klaria Pharma news releases